Search

Find exactly what you’re looking for.
Search

Service
Showing 201-213 of 213 results

This is a summer when many employees (and employers) may be done with COVID-19, but the virus is not done with us. While government mandates have virtually disappeared, the expected surge of omicron variants during 2022, and the resulting increase in absenteeism due to illness and quarantine...

New Jersey’s landmark Environmental Justice Law, N.J.S.A. 13:1D-157 (“EJ Law”), signed by Governor Murphy in September 2020, authorizes the NJDEP to deny or condition certain permits based on an assessment of a “facility’s” contribution to environmental and public health impacts in the State’s...

On May 13, 2022, Governor J.B. Pritzker signed Senate Bill 3146, amending the Illinois “One Day Rest in Seven” Act into law. Shortly after, Governor Pritzker signed into law Senate Bill 3120, the Family Bereavement Leave Act, which amends the Child Bereavement Leave Act. Illinois employers should be...

On June 29, 2022, the U.S. Department of Health and Human Services Office for Civil Rights released two guidance documents addressing (1) disclosures under the HIPAA Privacy Rule relating to reproductive health care (“Disclosure Guidance”), and (2) the privacy and security of reproductive health...

$269 Million Construction Loan for South Florida Mixed-Use Project Is Among Largest of Its Kind “This transaction underlines the strength of Peter [Baytarian]’s vision and the importance of the Nautilus 220 project to the area,” said Anthony Kang, a partner with Saul Ewing.

Law360 (June 27, 2022, 9:18 PM EDT) -- As the calendar flips to the second half of 2022, the National Labor Relations Board is poised to revisit issues including its bargaining order standards and the validity of so-called captive audience meetings, and a New York judge is mulling a landmark...

Washington, D.C., November 24, 2021 – Saul Ewing LLP served as counsel to Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) in the successful completion today of its previously announced $450 million acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS). The acquisition strengthens Supernus'...

For More Information
Contact us